



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
R. Admiraal,  
✉ r.admiraal-4@prinsesmaximacentrum.nl

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 05 June 2024  
ACCEPTED 28 June 2024  
PUBLISHED 06 August 2024

CITATION  
Meesters-Ensing JI, Admiraal R, Ebskamp L, Lacna A, Boelens JJ, Lindemans CA and Nierkens S (2024), Corrigendum: Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept.  
*Front. Pharmacol.* 15:1444228.  
doi: 10.3389/fphar.2024.1444228

COPYRIGHT  
© 2024 Meesters-Ensing, Admiraal, Ebskamp, Lacna, Boelens, Lindemans and Nierkens. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept

J. I. Meesters-Ensing<sup>1†</sup>, R. Admiraal<sup>1,2\*†</sup>, L. Ebskamp<sup>3</sup>, A. Lacna<sup>3</sup>, J. J. Boelens<sup>4</sup>, C. A. Lindemans<sup>1,2</sup> and S. Nierkens<sup>1,3</sup>

<sup>1</sup>Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, <sup>2</sup>Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, <sup>3</sup>Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, <sup>4</sup>Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, United States

## KEYWORDS

anti-thymocyte globulin (ATG), TDM (therapeutic drug monitoring), stem cell transplant (SCT), antibody, pediatrics-children

## A Corrigendum on Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept

by Meesters-Ensing J, Admiraal R, Ebskamp L, Lacna A, Boelens JJ, Lindemans CA and Nierkens S (2022). *Front. Pharmacol.* 13:828094. doi: 10.3389/fphar.2022.828094

In the published article, there was an error. The unit of AUC used throughout the paper is incorrect.

A correction has been made to the sections “**Patients eligible for TDM and simulation for the calculated optimal dose,**” (paragraph 3) “**Therapeutic drug monitoring**” (paragraph 2) and to the footnotes of **Table 1**. The unit for AUC previously stated:

“AU\*day/L”

The corrected unit for AUC appears below:

“AU\*day/mL”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.